Johnson & Johnson signs the first-ever MoU with HCMC oncology hospital to unlock access to innovative cancer treatment
Ho Chi Minh City, 11 September 2025 - Johnson & Johnson (Vietnam) Co., Ltd. ("Johnson & Johnson Vietnam") has signed the first-ever Memorandum of Understanding (MoU) with Ho Chi Minh City (HCMC) Oncology Hospital to strengthen their collaboration, especially in addressing two of Vietnam's most pressing health challenges: lung cancer and prostate cancer. This landmark agreement marks Johnson & Johnson Vietnam's first formal collaboration focused on improving cancer care in the country. It reflects the company's commitment to bringing innovative medicine to improve lives in Vietnam and unlocking access to advanced treatment through local collaboration.
Latest
 |
The newly signed MOU outlines several areas of collaboration between Johnson & Johnson Vietnam and HCMC Oncology Hospital. The strategic partnership will focus on optimising treatment pathways for lung and prostate cancers to streamline processes and improve patient experience and outcomes. It will support increased awareness and diagnosis of EGFR exon 20 insertion mutations in NSCLC, and expand the adoption of next-generation sequencing (NGS) testing. The collaboration will also strengthen medical knowledge-sharing and training and build confidence among healthcare professionals in prescribing novel therapies. Multidisciplinary collaboration will be enhanced by engaging oncologists, pathologists, surgeons, radiologists, clinical pharmacists, and nurses to ensure holistic patient care. Furthermore, the MOU will reinforce referral pathways between HCMC Oncology Hospital and its 13 satellite hospitals across the Mekong Delta, Southeast and Central regions to help patients receive earlier and more accurate diagnoses.
 |
Mr. Upendra Patkie, General Director of Johnson & Johnson Vietnam, shared: "At Johnson & Johnson, everything starts with the patient. Recognising the urgent needs of those living with lung and prostate cancer – two of the most prevalent and life-altering diseases in Vietnam- we are committed to delivering innovative treatments that not only extend life but also improve its quality. Through our MOU with HCMC Oncology Hospital, we are proud to unlock access to these breakthrough therapies, helping more patients receive the care they need. This MOU underscores our unwavering belief that patients deserve more time with their loved ones. Together, we are working to transform cancer care and build a healthier future for communities across Vietnam."
Cancer remains a significant public health burden in Vietnam. According to GLOBOCAN, lung cancer is the third most commonly diagnosed cancer in Vietnam, with more than 24,000 new cases diagnosed in 2022. It is also the second leading cause of cancer-related deaths, claiming more than 22,000 lives in the same year. Alarmingly, about three-quarters of lung cancer patients are diagnosed at advanced stages, where treatment options are limited and survival rates are poor. Non-small cell lung cancer (NSCLC) accounts for 80 to 85 per cent of lung cancer cases. Among them, patients with rare genetic alterations such as EGFR exon 20 insertions face even greater challenges. These mutations often resist standard therapies, leaving limited treatment options and poorer prognoses than more common EGFR mutations. This context underscores the importance of advancing molecular testing, precision medicine, and new therapeutic approaches.
 |
Meanwhile, prostate cancer is a growing concern for men in Vietnam. In 2022, the country reported nearly 5,900 new cases, making it the fifth most common cancer for males and 2.3 per cent of all cancer-related deaths. These figures highlight the urgent need to improve awareness, early detection, and more effective treatment strategies.
ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, treatments are more innovative and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
Learn more at www.jnj.com or at www.janssen.com/johnson-johnson-innovative-medicine. Follow us at @JNJInnovMed.
Johnson & Johnson (Vietnam) Co., Ltd. is a Johnson & Johnson company
